$SUJA

Roth/MKM initiates Suja Life stock with buy rating on margin outlook

Roth/MKM initiated coverage on Suja Life (NASDAQ:SUJA) with a buy rating and $20 price target, citing its portfolio and growth outlook. The stock is currently at $9.05, with a potential upside of 121%. Suja reported Q2 2026 net sales of $83.9M, up 11.6%, and adjusted EBITDA of $14.6M, up 50%, but noted grocery demand decline.

Original reporting
Published Oct 2, 2026, 7:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 7:12 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SUJA
Bullish
high confidence
Mentioned
$SUJA
Relevance
6/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SUJABullishMed
01

Why it matters

The buy rating and $20 target imply a 121% upside from the current price, suggesting a catalyst for short‑term buying.

02

Market read

New coverage and strong quarterly metrics provide a fresh catalyst for SUJA, potentially driving price appreciation.

03

What to watch

Potential headwinds in the grocery channel and channel concentration risk could limit upside.

Relevance 6/10Novelty 6/10Timing: pre-market today

Background

Suja Life (NASDAQ:SUJA) is a cold‑pressed beverage maker that recently reported Q2 2026 results and received a new analyst rating.

Company-level read

Ticker impact

$SUJABullishHigh confidence
Context

Roth/MKM initiated coverage with a buy rating and $20 price target after Suja Life reported Q2 2026 sales up 11.6% and adjusted EBITDA up 50%.

Expected impact

likely upward pressure as investors price in the new target and margin inflection.

Evidence & confidence

The coverage note provides a concrete valuation and highlights margin improvement, which can drive buying interest.

Market effects

Healthy beverage sector may see renewed interest as Suja's growth outpaces category.

U.S. consumer discretionary stocks could benefit from the positive coverage.

Limited to U.S. small‑cap investors; no broader macro impact.

Counterpoint

The stock remains volatile after a 49% six‑month decline; valuation may still be stretched.

Key entities

  • Roth/MKM

    Initiated coverage with a buy rating on Suja Life.

Related articles

Med

Suja Life’s Recent Volatility Masks A Longer Game In Functional Beverages

Suja Life's stock fell to $9 from $18 after lowering full-year guidance due to grocery channel weakness. Investors are exploring lawsuits, citing potential misleading information. Despite Q2 sales growth of 11.6% to $83.9M, sequential sales dropped 21%. The company remains optimistic about its long-term strategy in the functional beverage market, which is expected to reach $400B by 2034.

$SUJAMed

Suja Defies Grocery Slowdown With Double-Digit Sales Growth in Q2

Suja Life, Inc. (Nasdaq: SUJA) reported Q2 net sales up 11.6% year over year to $83.9 million, citing volume growth and improved distribution. Gross profit increased 9.9% to $39.2 million, or 46.7% of sales. The company raised its 2026 outlook to $360 to $369 million net sales from $326.6 million in 2025.

$SUJAMed

Suja Life Reports Second Quarter 2026 Financial Results

SUJA LIFE, INC. (SUJA) filed an SEC Form 8-K — Results of Operations and Financial Condition. Suja Life Reports Second Quarter 2026 Financial Results Net sales increased 11.6% year-over-year to $83.9 million Updates fiscal year 2026 outlook OCEANSIDE, CA, August 4, 2026 – Suja Life, Inc. (NASDAQ: SUJA) (“Suja Life,” “Suja” or the “Company”), a leading better-for-you bever

$SUJAMedAI 9/10

Suja Life Reports First Quarter 2026 Financial Results

Suja Life (NASDAQ: SUJA) reported first-quarter 2026 net sales of $107.1 million, up 22.5% year over year from $87.4 million. Adjusted EBITDA rose 66.3% to $25.0 million, with margin expanding to 23.4%. Net income was $7.7 million versus a prior-year net loss. The company initiated 2026 guidance: net sales $367–$371 million and Adjusted EBITDA $70–$72 million.

$SUJAMed

Suja Life (NASDAQ:SUJA) Upgraded to “Strong-Buy” at Evercore

Evercore upgraded Suja Life (NASDAQ:SUJA) to a “strong-buy” rating in a Monday research note, according to Zacks.com. Other firms also initiated coverage: Goldman Sachs set a $31 target and a “buy,” Jefferies set a $25 target and a “buy,” and William Blair rated “outperform.” MarketBeat data show a consensus “Buy” and average target $26.67.

$NVDAMed

Here are Monday's biggest analyst calls: Nvidia, Apple, Tesla, Broadcom, Microsoft, IBM, Meta, Tyson Foods & more

Wall Street analysts issued multiple calls Monday. Goldman initiated HawkEye 360 as buy; Morgan Stanley upgraded Dell to equal weight; Wells Fargo upgraded Tandem Diabetes Care to overweight. Citizens initiated Microsoft at Market Outperform with a $550 target; Barclays initiated IBM at overweight with a $350 target. Cantor reiterated Tesla overweight; RBC reiterated Meta outperform. Broadcom was reiterated overweight by Morgan Stanley, raising its target to $485.